Rapid Diagnosis of CSF Lymphoma via Liquid Biopsy

CNS Lymphoma CNS Lymphoma can be a challenging diagnosis, and delays in diagnosis are often incurred.

CNS Lymphoma

Recently, the Shankar Lab in CERES highlighted the extent of this problem and a new solution for rapid diagnosis of CNS lymphoma. In a new publication in the journal Blood https://pubmed.ncbi.nlm.nih.gov/33735913/, lead author Mihir Gupta led the characterization of a new strategy for CNS lymphoma diagnosis based on early detection of canonical MYD88 mutations. At CERES, we believe this strategy will lead to earlier and more rapid diagnosis of CSF lymphoma. In a recent case, a patient presented to Mass General with enhancement and FLAIR signal changes in the midbrain, thalamus, and basal ganglia. On a research protocol, the patient was found to be MYD88 positive just 12 hours after presentation, confirming the presence of this key mutation signature of CNS lymphoma. The CERES team, led by Dr. Shankar in collaboration with the MGH Pathology Dept is developing a CLIA certified version of this assay. Mihir Gupta M.D.Dr. Ganesh Shankar

Boston Exosome Hub

Boston Exosome Hub The CERES team will be presenting at the NIH's 2021 annual Liquid Biopsy Consortium steering committee meeting this coming week. We'll be highlighting a few members of the Boston Exosome Hub including the Lee/Castro Lab, the Balaj/Carter Lab, and Dr. Johan Skog of Exosome Diagnostics. Boston has been an "ExoHub" for exosome research since the 2008 publication of the discovery of exosomes being shed from glioblastoma tumors and intercellular transmission of exosomal RNA. The community of exosome researchers has now greatly enlarged in Boston and worldwide. Exosomes In addition, to the Boston team, we will hear from a great lineup of experts in liquid biopsy including a session on:

Liquid Biopsy: From Bench to Commercialization
  • Division Director: Philip Castle, MPH, PhD, Division of Cancer Prevention, NCI

  • Chief, CBRG: Sudhir Srivastava, MPH, PhD, Division of Cancer Prevention,NCI

  • Program Introduction: Lynn Sorbara, PhD, Division of Cancer Prevention, NCI

  • Nick Papadopoulas, PhD – Johns Hopkins University School of Medicine and Abhijit Patel, MD, PhD – Yale University. “Liquid Biopsy for the Detection of Cancer: From Bench to Clinical Application”

  • Richard Cote, MD – Washington University School of Medicine. “Toward the Translation of Circulating Tumor Cells into Clinically Actionable Biomarkers”

  • Johan Skog, PhD – CSO, Exosome Diagnostic, “Current Synergies of Liquid Biopsies, a Multi-analyte Approach to Early Detection”

  • Charles “Buck” Strom MD, PhD – CEO, Liquid Diagnostics

  • Plenary Keynote: Victor E. Velculescu MD, PhD Johhs Hopkins University School of Medicine

Diagnostics Derived from Extracellular Vesicles

Development PhasesIn this article, lead author Anudeep Yekula and co-authors from Ceres describe the process of developing clinical diagnostics based on extracellular vesicles.

Complexities in this process derive from the need to standardize the isolation, characterization, and biofluid sampling protocols when working with EVs. In a recent NIH R01 grant to the Ceres Lab, we are undertaking a series of studies to i) address variability among the different EV isolation methods and platforms currently available, and to ii) pinpoint to the “best” method to validate candidate biomarkers for glioma diagnosis.

Ceres Research

CERES is a liquid biopsy research team at Massachusetts General Hospital.

The Ceres Research team focuses on bringing the power of liquid biopsy to the clinic for neurologic disorders. As one example, brain tumors reveal their presence in multiple ways. Liquid Biopsy is a tool to understand brain tumor signatures for the purpose of diagnosis and to gauge the efficacy of our therapies. CERES is led by a group of investigators focused on advancing clinical care by studying the nano-signatures of brain tumors as they are released into plasma and cerebrospinal fluid. Novel exosome, cell free nucleic acid, and protein based biomarkers are already beginning to change clinical practice.

Check back here for more updates on our work.